相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients
Alberto Puccini et al.
CANCERS (2022)
Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study
Pedro L. S. Uson Jr et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2021)
Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
Ning Ren et al.
FRONTIERS IN ONCOLOGY (2021)
Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis
Labrinus van Manen et al.
BIOMARKERS (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Michael J. Pishvaian et al.
LANCET ONCOLOGY (2020)
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Panagiotis Sarantis et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C
Xiaomin Chen et al.
CELL DEATH & DISEASE (2020)
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
Li-Tzong Chen et al.
CANCERS (2019)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Rachna T. Shroff et al.
JCO PRECISION ONCOLOGY (2018)
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
Mark Yarchoan et al.
ONCOTARGET (2017)
Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy
Long Ge et al.
BMJ OPEN (2017)
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
E. G. Chiorean et al.
ANNALS OF ONCOLOGY (2016)
PARP inhibitor combination therapy
Amy Drean et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
Masahiko Tanabe
CASE REPORTS IN ONCOLOGY (2016)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation
Vladimir M. Moiseyenko et al.
MEDICAL ONCOLOGY (2014)
A New Mechanism of Action for the Anticancer Drug Mitomycin C: Mechanism-Based Inhibition of Thioredoxin Reductase
Manuel M. Paz et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2012)
Genetic susceptibility to pancreatic cancer
Alison P. Klein
MOLECULAR CARCINOGENESIS (2012)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Homologous recombination in cancer development, treatment and development of drug resistance
Thomas Helleday
CARCINOGENESIS (2010)
Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer
Suee Lee et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Sian Jones et al.
SCIENCE (2009)
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor
MS van der Heijden et al.
CLINICAL CANCER RESEARCH (2005)
分享论文
